Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Innervace
AddedFeb 17, 2024
UpdatedJun 18, 2026
Innervace

Innervace

Series A

Innervace: Developing implantable, tissue-engineered solutions for neurodegenerative disorders since 2018.

HQ
New York City, NY, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Innervace, founded in 2018, is a regenerative therapy company dedicated to developing implantable, tissue-engineered solutions for neurodegenerative disorders. The company's core mission is to create anatomically inspired living scaffolds for brain pathway reconstruction, with a vision to revolutionize treatment for conditions like Parkinson's disease. Innervace's lead clinical product is a tissue-engineered nigrostriatal pathway designed to mimic the lost connections in patients with Parkinson's, aiming to restore functionality and improve quality of life.

Notable affiliated individuals include leading scientists and medical professionals specializing in neurodegenerative diseases. The company has garnered significant attention and investment from key players in the biotech and medical fields. Among its achievements, Innervace has successfully advanced its pre-clinical trials and is on the path to initiating clinical trials. The overall impact of Innervace lies in its potential to offer groundbreaking treatments that could significantly alter the landscape of neurodegenerative disease management.

Innervace - Similar Companies

Convalesce logo

Convalesce

convalesce.co

Regennova logo

Regennova

regennova.com

Enterin logo

Enterin

enterininc.com

Renerva logo

Renerva

renerva.com

Neuraly logo

Neuraly

neuralymed.com

Innervo Technology logo

Innervo Technology

Inner Cosmos logo

Inner Cosmos

innercosmos.io

Nia Therapeutics logo

Nia Therapeutics

Neuvivo logo

Neuvivo

neuvivo.com

Pipeline Therapeutics logo

Pipeline Therapeutics

Neurvana Medical logo

Neurvana Medical

Innox logo

Innox

innoxpharma.com

NeuraLace Medical logo

NeuraLace Medical

Cordance Medical logo

Cordance Medical

Precision Neuroscience logo

Precision Neuroscience

precisionneuro.io

Innervace - Quick Facts

Who are Innervace's competitors?

Companies similar to Innervace include Convalesce, Regennova, Enterin and Renerva.

When was Innervace founded?

Innervace was founded in 2018.

Where is Innervace's headquarters located?

Innervace's headquarters is located in New York City, NY, US.

When was Innervace's last funding round?

Innervace's most recent funding round was for $40M (USD) in September 2022.

How much has Innervace raised to-date?

As of Sep 8, 2022, Innervace has raised a total of $40M (USD).

How many employees does Innervace have?

Innervace has 7 employees as of Feb 5, 2024.

Innervace - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified